Archis is led by a strong and visionary management. Our management has more than two decades of experience in the pharmaceutical R&D, Drug development and commercial sectors.
Dr. Kovi has over 20 years of experience in diversified areas of pharmaceutical R&D, and Drug Development processes. He currently serves as the President and CEO of Apicore US LLC where he was able to achieve significant revenue growth year over year, mainly by the combination of commercializing the API products world-wide and achieving ANDA development partnership project deals with multiple established medium and big pharma partners. In this role, Dr. Kovi was primarily responsible for identifying new molecules and securing partnerships for aggressively moving up the value chain by embarking on New Drug Applications for the developments of New Drugs. Prior to Apicore, Dr Kovi had successful stints in Branded as well as generic Pharmaceuticals in India, as a scientist at Torrent Research Centre and Orchid Pharmaceuticals, before moving to the US where he worked as a Scientist at Biogen and as an Investigator at Vertex Pharmaceuticals Inc.
Dr. Kovi was also successful in securing investments of approximately $23 million USD from brand companies and investing firms as an equity and debt combination into Apicore. In October 2017, Apicore US LLC was sold to a large pharmaceutical company, which resulted in significant ROI to the shareholders and employees. Dr Kovi, has also founded RK Pharma Inc, a vertically integrated Pharmaceutical group, with expertise in manufacturing Key Starting Materials, Intermediates, API’s and finished dosage forms. Recently RK Pharma Inc leased Pfizer’s Pearl River manufacturing facility to manufacture finished dosage forms and, setup Archis Pharma LLC to commercialize the groups and other in-licensed products.
Dr. Kovi received his Masters of Pharmacy degree from the Birla Institute of Technology and Sciences Pilani, India. He received his Ph.D. from the M.S University in Vadodara, India. Dr. Kovi has published several research papers and has numerous patents in his name.
Dr. Thomas has over 20 years of experience in research leadership and strategic planning in the areas of bio-pharma R&D, Product development and therapeutic target discovery and validation. Dr. Thomas has held senior executive positions at Torrent Pharmaceuticals Research Centre, India, where he led teams responsible for setting up biological assays and managing pharmacokinetic and toxicological studies. In his prior role with CentreStone Ventures, a life science focused venture capital fund, Dr. Thomas has been actively involved in the scientific assessment and feasibility of various business opportunities, sourcing new opportunities, and taking leadership positions with investee companies - Medicure Inc., (VP Strategic Development), Marsala Biotech Inc., (President & CEO) etc., and helped create WaverleyPharma Inc (President & CEO), an oncology focused generic company and getting it listed on the Toronto Stock Exchange through an IPO. In addition, he has been responsible for the scientific evaluation of various assays/technologies for license or acquisition from industry and academia.
Dr. Thomas received his Master of Pharmacy degree and Ph.D. from the Birla Institute of Technology and Sciences, Pilani, India. He received his post-doctoral training at the Faculty of Medicine, University of Toronto. More recently he was awarded an MBA from the Ivey School of Business, London, Ontario. Dr Thomas also serves on the board of a couple of social & cultural enterprises and has led several community-focused volunteering efforts.